On September 12, 2025, Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), announced the pricing of its upsized underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $40.00 per share. All of the shares to be sold in the offering are to be sold by Avidity. The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $600 million. Wilson Sonsini Goodrich & Rosati is advising Avidity Biosciences on patent matters related to the transaction.

Avidity intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, to advance the development of its three late-stage clinical programs, to build appropriate commercial inventory levels to support multiple potential launches, to expand its commercial infrastructure, to progress research and development associated with its AOC platform, and for working capital and general corporate purposes.

The Wilson Sonsini team that is advising Avidity Biosciences on patent matters related to the transaction was led by Minyoung Shin and Mike Hostetler. The team also includes Hee Min Noh, Cassidy Evaristo, and Jen Zeng.

For more information, please see Avidity Biosciences’ news release.